Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

systemic-onset juvenile idiopathic arthritis (SoJIA) - Clinical Profile, Genes & Research | Kisho | Kisho

Rare Disease

systemic-onset juvenile idiopathic arthritis

MONDO:0019434

Also known as:SoJIAStill diseasesJIA

Find Clinical TrialsTrials

Overview

Systemic-onset juvenile idiopathic arthritis is marked by the severity of the extra-articular manifestations (fever, cutaneous eruptions) and by an equal sex ratio.

TreatmentsNo approved treatments · 4 in pipeline

Clinical Trials18 registered · 8 recruiting

Diagnosis

Biomarker and diagnostic research for systemic-onset juvenile idiopathic arthritis has been reported in the published literature.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

No approved treatments are currently available for systemic-onset juvenile idiopathic arthritis. An additional 4 compounds hold orphan drug designation.

Orphan Drug Designations

While no drugs are FDA-approved specifically for systemic-onset juvenile idiopathic arthritis, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.

The following drugs have received orphan drug designation from the FDA for systemic-onset juvenile idiopathic arthritis. Orphan designation reflects regulatory interest and does not indicate approval for treatment.

Brand Name	Generic Name	Sponsor

Prognosis

Estimated prevalence: 1-9 in 100,000 (Uncommon).

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

18 clinical trials registered, 8 recruiting. Interventions under study include other interventions, drug therapy, and biologic therapy. Pipeline includes 3 PHASE3, 2 PHASE2, 1 NA. Research is sponsored by a mix of industry and academic institutions.

NCT ID	Title	Phase	Sponsor	Status
[NCT05609630](https://clinicaltrials.gov/study/NCT05609630)

Data assembled from 5 of 12 sources · Last updated Sep 20, 2026, 8:41 AM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

External Resources

Orphanet

European rare disease database

Orphanet:85414

GARD

Genetic and Rare Diseases Info Center

GARD:10966

Questions for Your Care Team

→Are any of the 18 active clinical trials a good fit for my situation?
→With 4 compounds in the orphan drug pipeline, which are furthest along in development and which clinical trials should I be aware of?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Research Type	Count	% of Total
Patient case studies	25	34%
Disease patterns and progression	12	16%
Research summaries	11	15%
Laboratory research	10	14%
Other research	6	8%
Testing and diagnosis research	6	8%
Clinical study results	3	4%
New treatment approaches	1	1%

Kisho

systemic-onset juvenile idiopathic arthritis

Overview

Diagnosis

Treatment

Orphan Drug Designations

Prognosis

Research Landscape

Medical References

External Resources

Orphanet

GARD

Questions for Your Care Team

Questions for Your Care Team

Clinical Trials

Recent Publications

Latest News & Developments

Corrigendum to "Transition of serum-free IL-18 levels in systemic juvenile idiopathic arthritis measured by a novel detection method" [Cytokine 201 (2026) 157128].

Distinct cytokine and chemokine alterations in bronchoalveolar fluid from patients with systemic juvenile idiopathic arthritis associated lung disease (SJIA-LD).

2016 sJIA-MAS criteria and a step-up therapeutic approach in KD-MAS: insights from a combined cohort and literature review.

systemic-onset juvenile idiopathic arthritis

Overview

Diagnosis

Treatment

Orphan Drug Designations

Prognosis

Research Landscape

Medical References

External Resources

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Clinical Trials

Recent Publications

Latest News & Developments

Corrigendum to "Transition of serum-free IL-18 levels in systemic juvenile idiopathic arthritis measured by a novel detection method" [Cytokine 201 (2026) 157128].

Distinct cytokine and chemokine alterations in bronchoalveolar fluid from patients with systemic juvenile idiopathic arthritis associated lung disease (SJIA-LD).

2016 sJIA-MAS criteria and a step-up therapeutic approach in KD-MAS: insights from a combined cohort and literature review.